ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220104005104/en/
(Photo: Business Wire)
“This is the fourth IND approval for our investigational drug Nantheia™ product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications. This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “We are excited to be working with the UCLA team and look forward to this trial advancing.”
This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D ., Professor of Psychiatry and Biobehavioral Sciences at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA. Funding for this trial is from the National Institute on Drug Abuse (NIDA). (Clinical Trials.gov Identifier: NCT03787628 )
“The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic,” said Dr. London.
“With the IND approved we are now moving quickly to get the trial under way,” said Dr. De La Garza.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder. The company employs patented delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. Jerusalem, Israel) to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion into additional markets such as the EU, China, Africa, and other countries in Asia. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005104/en/
Contact information
ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Strengthens Valuation Capabilities in Asia Pacific with ETC9.12.2025 16:30:00 EET | Press release
Andersen Global continues to expand its presence in Asia Pacific through a Collaboration Agreement with Edmund Tie & Company (ETC), a full-service real estate advisory firm headquartered in Singapore. Established in 1995, ETC delivers valuation and advisory services across the real estate lifecycle, including statutory and corporate valuation, investment advisory, feasibility studies, and property tax advisory. Operating across Singapore, Malaysia, and Thailand, ETC combines deep regional knowledge with international standards to support developers, investors, private and sovereign funds, corporations, REITs, and owners and occupiers. Known for its research-driven approach and integrated service model, the firm helps clients navigate regulatory complexity and optimize asset value. “Our strength lies not just in technical execution, but in helping clients see the full picture—connecting market signals, regulatory shifts, and long-term value drivers,” said Desmond Sim, CEO of ETC. “Colla
Grid Dynamics Signs Strategic Collaboration Agreement with AWS to Advance Data Foundations for Generative AI9.12.2025 16:15:00 EET | Press release
Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a premier IT consulting and digital services provider, today announced it has entered into a multi-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS). The agreement focuses on enabling and scaling generative AI journeys for enterprise companies, extending a 15-year relationship between the companies. The collaboration provides Grid Dynamics access to the AWS Data Foundations for Generative AI Program, established to help organizations build the robust, governed, and high-quality data infrastructures required to adopt and scale AI. By combining the AWS suite of cloud-native data and AI services and Grid Dynamics’ deep expertise in data engineering, analytics, and AI/ML, enterprises can accelerate their progress in AI from experimentation to full-scale production. As a recognized AWS Partner with deep technical expertise and proven customer success, Grid Dynamics expects to play a pivotal role in enabli
Indero Named Best Employer by Mercer9.12.2025 16:00:00 EET | Press release
Indero, a global CRO specializing in dermatology and rheumatology, has been honored by Mercer, recognizing its excellence as a Best Employer. Indero is proud of its long-term commitment to building a workplace culture defined by trust, fairness, and meaningful employee experiences and believes this distinction reflects its positive impact in 2025. The Best Employers in Canada – Powered by Mercer certification program recognizes organizations that consistently deliver a positive and engaging employee experience, based on employee feedback. The degree of employee engagement is a crucial factor for both current and prospective clients and partners, since motivated and committed employees are more likely to excel in their roles and ensure the highest standards in the organization’s products and services. Formerly known as the Kincentric Best Employers, the program has highlighted Canada’s top workplaces for over 25 years and now benefits from Mercer’s expanded global reach and one of the m
Gulf Oil Selects DataXstream’s OMS+ Portal to Power LATAM Digital Transformation9.12.2025 15:33:00 EET | Press release
DataXstream LLC, an SAP® Endorsed App partner developing innovative solutions for SAP sales and distribution, today announced that Gulf Oil, a globally recognized lubricant company with operations in more than 25 countries, has selected OMS+ Portal to modernize and unify the company’s customer-facing sales platform across Latin America. The project is part of a broader initiative to streamline operations, enhance scalability and deliver a seamless buying experience that is fully integrated with SAP S/4HANA. As Gulf Oil continues its footprint across LATAM, the company needed a solution that would not only elevate the customer experience, but also provide the flexibility and performance needed to scale. OMS+ Portal will serve as the central platform for Gulf’s distributor network, offering a unified, SAP-embedded environment for self-service ordering and real-time collaboration. “We chose OMS+ Portal because it is a certified SAP partner that will help us to scale the customer portal ac
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy9.12.2025 15:05:00 EET | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer on-site liquid biopsy testing based on Guardant360® CDx technology. The collaboration expands access to precision oncology diagnostics and supports both routine care and clinical research. FPG 360 is one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. Policlinico Gemelli, one of Italy's largest and most renowned hospitals, serves thousands of cancer patients each year at its com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom